DMRA
Healthcare BiotechnologyDamora Therapeutics, Inc.
$20.22
-0.52 -2.50% today
Price History
Not enough data
Key Stats
Market Cap
1.25B
Avg Volume
536,317
EPS
-$0.25
52W High
$38.33
52W Low
$4.95
Div. Yield
0.0%
Analyst Ratings
Buy1
Str Buy
9
Buy
0
Hold
0
Sell
0
Str Sell
Valuation
Forward P/E
-9.31
P/B Ratio
3.23
EV/EBITDA
-8.70
Margins
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Equity
(99.7%)
Return on Assets
(21.6%)
Liquidity & Leverage
Current Ratio
19.73
Quick Ratio
19.65
Total Cash
540.52M
Total Debt
0
About
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
www.damoratx.com